Sam Ghilardi 1/20/26 Sam Ghilardi 1/20/26

All About Watertown's VC Funding

2025 Funding numbers are in, 2026 early raises, Lyra Therapeutics runs out of time and more

Sam Ghilardi 1/13/26 Sam Ghilardi 1/13/26

Watertown Bio Journal Club: How Targeted is Targeted Protein Degradation?

Evaluating the potential impact of off-target degradation of KT-474

Sam Ghilardi 1/6/26 Sam Ghilardi 1/6/26

Neumora's positive clinical data , new tenants at the Arsenal, and more

Sam Ghilardi 12/16/25 Sam Ghilardi 12/16/25

A Multi-Million dollar public offering, the developing race for a dupilumab alternative, business awards, and more.

Sam Ghilardi 12/9/25 Sam Ghilardi 12/9/25

Plus, How to design a PROTAC

Sam Ghilardi 12/2/25 Sam Ghilardi 12/2/25

Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more

Sam Ghilardi 11/18/25 Sam Ghilardi 11/18/25

Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more

Sam Ghilardi 11/11/25 Sam Ghilardi 11/11/25

Talking about proteases, PROTACs, and molecular glues. Plus new methods for mass spec tagging, viral inhibitors, and more.

Sam Ghilardi 11/4/25 Sam Ghilardi 11/4/25

Soufflé Therapeutics Launches from Stealth, Disc and Werewolf receive FDA priority, Affini-T may be winding down.